Bristol-Myers Squibb

View All

pharma happenings for BMS Sanofi GW Pharmaceuticals Kiadis
Bristol Myers’ psoriasis drug; GW Pharmaceuticals eyes US market for Nabiximols; Karyopharm’s Xpovio; Kiadis USD 358M Buyout

Bristol Myers' Experimental Psoriasis drug succeeds in late-stage study defeats rival Amgen's Otezla Bristol Myers' experimental psoriasis drug, deucravacitinib has outmarched Amgen's Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial in patients with moderate to severe plaque psoriasis. Deucravaci...

Find More

MyoKardia & Eidos purchase; Amgen's Aimovig; HCV discovery; Bharat Biotech's Covaxin
MyoKardia buyout; Eidos acquisition; Amgen’s Aimovig; HCV discovery; Bharat Biotech’s Covaxin

MyoKardia Buyout: BMS expands its cardiovascular portfolio for USD 13.1 Billion  Bristol Myers Squibb has bounty years in a go with its shares skyrocketing as it decides to go on an acquisition spree.  BMS has announced to acquire MyoKardia, a pharmaceutical company leveraging precision medicine to ...

Find More

pharma news
Sanofi acquires Principia; FDA’s Nod to Roche’s Enspryng; BMS, Dragonfly’s Licensing Deal

New strategy, new outlook: Sanofi takes another step, gains full control over the Principia’s MS treatment  Sanofi has inked a definitive agreement with Principia Biopharma to acquire the company, all of its outstanding shares, and its BTK inhibitors in a deal worth USD 3.68 Billion. The deal is expected t...

Find More

Top-cancers-in-the-world
Top 5 Cancers Creating Major Challenge To The Global Healthcare System

Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer, and in 2018 was estimated to be responsible for 9.6 million deaths. Costing people quality of lives and eventually lea...

Find More

Prostate Cancer Market
Prostate Cancer Market Experiences an Influx of the Pharma Players Veering the Market Ahead

Prostate Cancer Market Size is Expected to Increase with a CAGR of 8.1% in the 7MM for the study period of 2017-30 owing to rich Pipeline, Increasing Awareness and Better Treatment Options. A malignancy of prostate glands, Prostate Cancer, develops slowly and remains confined to prostate glands, however, can inv...

Find More

Non-Small Cell Lung Cancer Market Insights
Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses

Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...

Find More

COVID-19-pipeline-development
COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market

The U.S. FDA has given its nod to Seattle Genetics for its Tukysa (tucatinib) for advanced unresectable or metastatic HER2-positive breast cancer Genetics Tukysa (tucatinib) is a tyrosine kinase inhibitor of the HER2 protein, administered orally in combination with chemotherapy agents trastuzumab and capec...

Find More

Pharma News
JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19

The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC)  The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...

Find More

Malignant pleural mesothelioma
Malignant pleural mesothelioma market: Elusive treatment approaches and Poor diagnosis

Malignant pleural mesothelioma (MPM) is a malignancy of pleural layers within the lung cavity and inner sides of the ribs.  Year of research has revealed asbestos exposure as the primary cause of the malignancy. The longer the asbestos exposure, more is the risk of a person developing mesothelioma.  It...

Find More

the business cocktail lemborexant
The Business Cocktail

EISAI now solely responsible for lemborexant Eisai today announced that its U.S. subsidiary has bought out  Purdue Pharma L.P.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multip...

Find More